Oncologic Sciences, University of South Florida, Tampa, USA; Department of Malignant Hematology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA.
Best Pract Res Clin Haematol. 2013 Sep;26(3):269-74. doi: 10.1016/j.beha.2013.10.007. Epub 2013 Oct 16.
A number of new agents in acute myeloid leukemia (AML) have held much promise in recent years, but most have failed to change the therapeutic landscape. Indeed, with the exception of gemtuzumab ozogamicin (which was subsequently voluntarily withdrawn from the commercial market), no new agent has been approved for acute myeloid leukemia (AML) beyond the 7 + 3 regimen, which was has been in use for over 40 years. This review touches upon the potential reasons for these failures and explores the newer therapeutic approaches being pursued in AML.
近年来，许多新型药物在急性髓细胞白血病（AML）中显示出巨大的应用前景，但大多数药物都未能改变治疗格局。事实上，除了吉妥珠单抗奥佐米星（随后被自愿从商业市场撤回）之外，没有任何新的药物被批准用于急性髓细胞白血病（AML），除了 7+3 方案，该方案已经使用了 40 多年。本文讨论了这些失败的潜在原因，并探讨了目前在 AML 中采用的新的治疗方法。
